prospectus out - cr of $0.20 per share, page-23

Hey ESPIN,

I'm assuming no reply from Tim Boyd?

He's prob too busy thinking about how he can help himself to more of our $$$.

Biosignal shareholders also approved a lucrative deal in March for current chairman and director Tim Boyd, who arranged the RGM acquisition, after Biosignal posted three years of operating losses.

He will receive a success fee of $150,000, as well as 200,000 share options and 200,000 shares to a nominee company.